Fascin expression predicts an aggressive clinical course in patients with advanced breast cancer

Min,Kyueng‑Whan; Chae,Seoung  Wan; Kim,Dong‑Hoon; Do,Sung‑Im; Kim,Kyungeun; Lee,Hyun  Joo; Sohn,Jin  Hee; Pyo,Jung‑Soo; Kim,Dong  Hyun; Oh,Sukjoong; Choi,Seon  Hyeong; Park,Yong  Lai; Park,Chan  Heun

doi:10.3892/ol.2015.3191

Fascin expression predicts an aggressive clinical course in patients with advanced breast cancer

Authors:
- Kyueng‑Whan Min
- Seoung Wan Chae
- Dong‑Hoon Kim
- Sung‑Im Do
- Kyungeun Kim
- Hyun Joo Lee
- Jin Hee Sohn
- Jung‑Soo Pyo
- Dong Hyun Kim
- Sukjoong Oh
- Seon Hyeong Choi
- Yong Lai Park
- Chan Heun Park
View Affiliations

Affiliations: Department of Pathology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Gyeonggi-do, Republic of Korea, Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, Department of Radiology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, Department of Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
Published online on: May 8, 2015 https://doi.org/10.3892/ol.2015.3191
Pages: 121-130
Copyright: © Min et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fascin is an actin cross-linking protein, which regulates actin dynamics and filopodia or spike formation, as well as the epithelial‑mesenchymal transition, and has been implicated in cell motility. Although, fascin is pivotal in mediating the aggressive behaviour of various types of cancer, its prognostic significance according to tumour stage has yet to be evaluated. Therefore, the present study investigated fascin expression in 194 patients diagnosed with invasive ductal carcinoma of the breast between 2000 and 2005. Fascin protein expression levels were evaluated by immunostaining on a tissue microarray, and the association between fascin expression and various clinicopathological parameters was analysed. Fascin expression was significantly correlated with various clinicopathological parameters, including high histological grade, tumour necrosis, resistance to adjuvant therapy, high expression of p53 and Ki‑67 and specific therapeutic markers (oestrogen and progesterone receptor negativity; all P<0.05). Furthermore, univariate and multivariate analyses identified a significant association between fascin expression, and poor disease‑free and overall survival, in late‑stage breast cancer (all P<0.05). Therefore, fascin may be crucial in predicting aggressive tumour behaviour, particularly in patients with advanced-stage disease that has acquired the properties of migration and invasion.

View Figures

View References

1	National Cancer Institute, . Cancer statistics: SEER stat fact sheets, breast cancer. http://seer.cancer.gov/statfacts/html/breast.html
2	Bouchalova P, Nenutil R, Muller P, et al: Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status. J Pathol. 233:238–246. 2014. View Article : Google Scholar : PubMed/NCBI
3	Harris L, Fritsche H, Mennel R, et al: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 25:5287–5312. 2007. View Article : Google Scholar : PubMed/NCBI
4	Lin Q, Liu Y, Chen H, et al: Survivin, Ki-67 and tumor grade as predictors of response to docetaxel-based neoadjuvant chemotherapy in locally advanced breast cancer. Mol Clin Oncol. 1:839–844. 2013.PubMed/NCBI
5	Mason BH, Holdaway IM, Mullins PR, Yee LH and Kay RG: Progesterone and estrogen receptors as prognostic variables in breast cancer. Cancer Res. 43:2985–2990. 1983.PubMed/NCBI
6	Ogston KN, Miller ID, Payne S, et al: A new histological grading system to assess response of breast cancers to primary chemotherapy: Prognostic significance and survival. Breast. 12:320–327. 2003. View Article : Google Scholar : PubMed/NCBI
7	Peppercorn J, Perou CM and Carey LA: Molecular subtypes in breast cancer evaluation and management: Divide and conquer. Cancer Invest. 26:1–10. 2008. View Article : Google Scholar : PubMed/NCBI
8	Feeley LP, Mulligan AM, Pinnaduwage D, Bull SB and Andrulis IL: Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information. Mod Pathol. 27:554–561. 2014. View Article : Google Scholar : PubMed/NCBI
9	Chambers AF, Naumov GN, Varghese HJ, et al: Critical steps in hematogenous metastasis: An overview. Surg Oncol Clin N Am. 10:243–255. 2001.PubMed/NCBI
10	Saaristo A, Karpanen T and Alitalo K: Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene. 19:6122–6129. 2000. View Article : Google Scholar : PubMed/NCBI
11	Woodhouse EC, Chuaqui RF and Liotta LA: General mechanisms of metastasis. Cancer. 80(Suppl): S1529–S1537. 1997.
12	Min KW, Kim DH, Do SI, et al: Diagnostic and prognostic relevance of MMP-11 expression in the stromal fibroblast-like cells adjacent to invasive ductal carcinoma of the breast. Ann Surg Oncol. 20(Suppl 3): S433–S442. 2013.PubMed/NCBI
13	Jiang P, Enomoto A and Takahashi M: Cell biology of the movement of breast cancer cells: Intracellular signalling and the actin cytoskeleton. Cancer Lett. 284:122–130. 2009. View Article : Google Scholar : PubMed/NCBI
14	Edwards RA and Bryan J: Fascins, a family of actin bundling proteins. Cell Motil Cytoskeleton. 32:1–9. 1995. View Article : Google Scholar : PubMed/NCBI
15	Mosialos G, Yamashiro S, Baughman RW, et al: Epstein-Barr virus infection induces expression in B lymphocytes of a novel gene encoding an evolutionarily conserved 55-kilodalton actin-bundling protein. J Virol. 68:7320–7328. 1994.PubMed/NCBI
16	Hashimoto Y, Skacel M and Adams JC: Roles of fascin in human carcinoma motility and signaling: Prospects for a novel biomarker? Int J Biochem Cell Biol. 37:1787–1804. 2005. View Article : Google Scholar : PubMed/NCBI
17	Hsu KF, Lin CK, Yu CP, et al: Cortactin, fascin, and survivin expression associated with clinicopathological parameters in esophageal squamous cell carcinoma. Dis Esophagus. 22:402–408. 2009. View Article : Google Scholar : PubMed/NCBI
18	Al-Alwan M, Olabi S, Ghebeh H, et al: Fascin is a key regulator of breast cancer invasion that acts via the modification of metastasis-associated molecules. PLoS One. 6:e273392011. View Article : Google Scholar : PubMed/NCBI
19	Hashimoto Y, Skacel M, Lavery IC, et al: Prognostic significance of fascin expression in advanced colorectal cancer: An immunohistochemical study of colorectal adenomas and adenocarcinomas. BMC Cancer. 6:2412006. View Article : Google Scholar : PubMed/NCBI
20	Pelosi G, Pastorino U, Pasini F, et al: Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer. Br J Cancer. 88:537–547. 2003. View Article : Google Scholar : PubMed/NCBI
21	Hashimoto Y, Shimada Y, Kawamura J, et al: The prognostic relevance of fascin expression in human gastric carcinoma. Oncology. 67:262–270. 2004. View Article : Google Scholar : PubMed/NCBI
22	Tong GX, Yee H, Chiriboga L, Hernandez O and Waisman J: Fascin-1 expression in papillary and invasive urothelial carcinomas of the urinary bladder. Hum Pathol. 36:741–746. 2005. View Article : Google Scholar : PubMed/NCBI
23	Tan VY, Lewis SJ, Adams JC and Martin RM: Association of fascin-1 with mortality, disease progression and metastasis in carcinomas: A systematic review and meta-analysis. BMC Med. 11:522013. View Article : Google Scholar : PubMed/NCBI
24	Grothey A, Hashizume R, Sahin AA and McCrea PD: Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer. Br J Cancer. 83:870–873. 2000. View Article : Google Scholar : PubMed/NCBI
25	Yoder BJ, Tso E, Skacel M, et al: The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course. Clin Cancer Res. 11:186–192. 2005.PubMed/NCBI
26	Esnakula AK, Ricks-Santi L, Kwagyan J, et al: Strong association of fascin expression with triple negative breast cancer and basal-like phenotype in African-American women. J Clin Pathol. 67:153–160. 2014. View Article : Google Scholar : PubMed/NCBI
27	Robbins P, Pinder S, de Klerk N, et al: Histological grading of breast carcinomas: A study of interobserver agreement. Hum Pathol. 26:873–879. 1995. View Article : Google Scholar : PubMed/NCBI
28	Edge SB, Byrd DR, Compton CC, et al: AJCC Cancer Staging Manual. 7th. Springer; New York, NY, USA: 2010
29	Allred DC, Harvey JM, Berardo M and Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 11:155–168. 1998.PubMed/NCBI
30	Carey LA, Perou CM, Livasy CA, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 295:2492–2502. 2006. View Article : Google Scholar : PubMed/NCBI
31	Wolff AC, Hammond ME, Hicks DG, et al: American Society of Clinical Oncology; College of American Pathologists: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 31:3997–4013. 2013. View Article : Google Scholar : PubMed/NCBI
32	Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 8:138–140. 1987.PubMed/NCBI
33	Jayo A and Parsons M: Fascin: A key regulator of cytoskeletal dynamics. Int J Biochem Cell Biol. 42:1614–1617. 2010. View Article : Google Scholar : PubMed/NCBI
34	Li A, Dawson JC, Forero-Vargas M, et al: The actin-bundling protein fascin stabilizes actin in invadopodia and potentiates protrusive invasion. Curr Biol. 20:339–345. 2010. View Article : Google Scholar : PubMed/NCBI
35	Matsudaira P: Actin crosslinking proteins at the leading edge. Semin Cell Biol. 5:165–174. 1994. View Article : Google Scholar : PubMed/NCBI
36	Vignjevic D, Schoumacher M, Gavert N, et al: Fascin, a novel target of beta-catenin-TCF signaling, is expressed at the invasive front of human colon cancer. Cancer Res. 67:6844–6853. 2007. View Article : Google Scholar : PubMed/NCBI
37	Oh SY, Kim YB, Suh KW, et al: Prognostic impact of fascin-1 expression is more significant in advanced colorectal cancer. J Surg Res. 172:102–108. 2012. View Article : Google Scholar : PubMed/NCBI
38	Puppa G, Maisonneuve P, Sonzogni A, et al: Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma. Br J Cancer. 96:1118–1126. 2007. View Article : Google Scholar : PubMed/NCBI
39	Roh MS, Um SJ, Choi Y, et al: Prognostic significance of fascin expression in stage I non-small cell lung cancer. Tuberc Respir Dis (Seoul). 65:105–109. 2008. View Article : Google Scholar
40	Xing P, Li JG, Jin F, et al: Fascin, an actin-bundling protein, promotes breast cancer progression in vitro. Cell Biochem Funct. 29:303–310. 2011. View Article : Google Scholar : PubMed/NCBI
41	Xie JJ, Xu LY, Wu JY, et al: Involvement of CYR61 and CTGF in the fascin-mediated proliferation and invasiveness of esophageal squamous cell carcinomas cells. Am J Pathol. 176:939–951. 2010. View Article : Google Scholar : PubMed/NCBI
42	Gu MJ, Kim JY and Park JB: Fascin expression predicts lymph node metastasis and worse survival in small intestinal carcinoma. Pathology. 46:21–24. 2014. View Article : Google Scholar : PubMed/NCBI